In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Difelikefalin | Natural peptide L-carnosine | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Skin and hair | Skin and hair | |
| Evidence | |||
| Amount of evidence | 272 | 1,203 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 123 (123 in people) | 34 (20 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 28 · 2 active | 2 | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Korsuva says: “Moderate to severe CKD-associated pruritus in adults receiving hemodialysis”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Difelikefalin | L-carnosine |
|---|---|---|
| Adverse eventsWhole body | 103103 | 251681 |
| Skin and hair |
PepBank is a research reference. Talk to a doctor before you use any peptide.
595621 |
33 |
| PharmacokineticsPharmacology | 24231 | 4820262 |
|---|
| Receptor activity and mechanismSkin and wound | 4211 | 16510362 |
|---|
| Inflammation markersSkin and wound | 8431 | 9714794 |
|---|
| Kidney functionKidney and urinary | 1212 | 761165 |
|---|
| Quality of lifeWhole body | 1919 | 11 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1313 | 11 |
|---|
| SleepSleep | 99 | 33 |
|---|
| MortalityWhole body | 761 | 55 |
|---|
| Blood pressureCardiovascular | 11 | 862 |
|---|
| Immune responseSkin and wound | 11 | 88 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Difelikefalin | L-carnosine |
|---|---|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 78% Treatment-emergent adverse events Placebo: 42% Dose studied: 0.5, 1.0, or 1.5 μg/kg thrice weekly8 weeksn not reported2020 | 30% Adverse events Placebo: 14% Dose studied: 2 g/day3 monthsn = 752012 |
78%
Treatment-emergent adverse events
Placebo: 42%
Dose studied: 0.5, 1.0, or 1.5 μg/kg thrice weekly8 weeksn not reported2020
30%
Adverse events
Placebo: 14%
Dose studied: 2 g/day3 monthsn = 752012
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Difelikefalin | L-carnosine |
|---|---|---|
| Quality of lifeWhole bodyCompared as: share of people in the arm that got the peptide, in % | 49% Patients with >=15-point Skindex-10 improvement · Black/AA patients, difelikefalin 0.5 µg/kg Black/AA patients, placebo: 28.9% Dose studied: 0.5 µg/kg12 weeksn = 2492024 |
No comparable result 1 randomized-trial result measure it in another way or another unit. |
| Skin and hairSkin and woundCompared as: difference from placebo, in nrs points | −0.97 NRS points Between-group difference in NRS change at week 4 Dose studied: 0.5 μg/kg three times per week6 weeksn = 1782023 | No randomized trial result 3 results from other study designs. |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 9% Incidence of treatment-emergent diarrhea Placebo: 5.7% Dose studied: 0.5 mcg/kgn = 8482022 | No randomized trial result 1 result from other study designs. |
|---|
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in % | 0.7% Deaths Placebo group: 1.2% Dose studied: 0.5 mcg/kgn = 8482022 | No randomized trial result 5 results from other study designs. |
|---|
49%
Patients with >=15-point Skindex-10 improvement · Black/AA patients, difelikefalin 0.5 µg/kg
Black/AA patients, placebo: 28.9%
Dose studied: 0.5 µg/kg12 weeksn = 2492024
No comparable result
1 randomized-trial result measure it in another way or another unit.
−0.97 NRS points
Between-group difference in NRS change at week 4
Dose studied: 0.5 μg/kg three times per week6 weeksn = 1782023
No randomized trial result
3 results from other study designs.
9%
Incidence of treatment-emergent diarrhea
Placebo: 5.7%
Dose studied: 0.5 mcg/kgn = 8482022
No randomized trial result
1 result from other study designs.
0.7%
Deaths
Placebo group: 1.2%
Dose studied: 0.5 mcg/kgn = 8482022
No randomized trial result
5 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 28 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Cara Therapeutics, Inc.473 participants17 Jul 2018 to 30 Mar 2020
Uremic Pruritus
Cara Therapeutics, Inc.378 participants20 Feb 2018 to 26 Mar 2020
Uremic Pruritus
Cara Therapeutics, Inc.288 participants14 Aug 2017 to 11 Feb 2020
Uremic Pruritus
2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Monash University40 participantsOct 2016 to est. Jul 2023
Poor Glycemic Control · Cardiovascular Risk Factors · Cognitive Function 1, Social
University of Louisville299 participants1 Apr 2018 to 1 Nov 2022
Air Pollution Toxicity